The FDA's approvals database records a supplement to Pfizer's new drug application for Zyvox (linezolid), dated 21 October. The record available to us does not state what the supplement changes; supplements commonly cover labelling, manufacturing or formulation updates.
A supplement is an administrative step on an existing approval. Without the label text, there is no basis to say the indication, dosing or safety advice has changed. Prescribers should check the updated label on the FDA site before assuming anything new.
Linezolid remains central to drug-resistant TB regimens in India, so label changes, when their content is known, are worth tracking.
- An FDA supplement to the linezolid application was recorded on 21 October.
- Its content is not stated in the record; check the FDA label before acting.
- A supplement is not a new indication.
- No CDSCO action is linked to this record.
Why it matters
Linezolid is widely used in drug-resistant TB, so any label change is relevant once its content is known.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free